Magnetic resonance investigation of bone marrow following priming and stem cell mobilization.

Abstract

PURPOSE:

To evaluate application of MRI and magnetic resonance spectroscopy (MRS) to monitor bone marrow cellularity during pretransplant priming with chemotherapy and hematopoietic growth factor (HGF) administration.

MATERIALS AND METHODS:

A total of 10 lymphoma and myeloma patients, in remission following induction therapy and considered eligible for high-dose therapy and autologous stem cell transplantation, were included in the study. MR investigation was scheduled four times: at study entry, and one, two, and four weeks following priming. Priming with cyclophosphamide and recombinant human granulocyte colony-stimulating factor (rhG-CSF) started the day after study entry. MR parameters studied in a region of interest were as follows: bone marrow intensity on short-time inversion-recovery (STIR) turbo spin-echo (TSE; thus STIRTSE) and on T1-weighted TSE (T1TSE) images, T2 value for fat component, T2 value for water component, water/fat ratio (W/F), T1 value for fat component, and T1 value for water component.

RESULTS:

The results did not support the hypothesis that hematopoietic expansion quantitated and monitored by MR correlates to the level of mobilized progenitor cells.

CONCLUSION:

The results indicate that release of stem cells is a more complex phenomenon than hematopoietic expansion and reduction of fat tissue in bone marrow.

• Authors: E Chabanova, H E Johnsen, L Meldgaard Knudsen, L Larsen, V Løgager, S Yingru, H S Thomsen
• Journal: Journal of magnetic resonance imaging : JMRI (J Magn Reson Imaging) Vol. 24 Issue 6 Pg. 1364-70 (Dec 2006) ISSN: 1053-1807 [Print] United States
• PMID: 17083110 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: (c) 2006 Wiley-Liss, Inc.

Chemical References

• Antineoplastic Agents
• Intercellular Signaling Peptides and Proteins
• Recombinant Proteins
• Granulocyte Colony-Stimulating Factor
• Cyclophosphamide

Topics

• Aged
• Antineoplastic Agents (therapeutic use)
• Bone Marrow Transplantation (methods, pathology)
• Cyclophosphamide (administration & dosage)
• Drug Therapy, Combination
• Female
• Granulocyte Colony-Stimulating Factor (administration & dosage)
• Humans
• Intercellular Signaling Peptides and Proteins (administration & dosage)
• Lymphoma (pathology, therapy)
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Premedication (methods)
• Recombinant Proteins
• Treatment Outcome